What's Happening

Sling Therapeutics has raised $123 million in Series C financing to advance its experimental oral drug linsitinib for people with thyroid eye disease (TED).

The financing will support a global Phase 3 clinical trial of linsitinib, which Sling is developing as an oral treatment for TED, a rare autoimmune condition that can cause swelling around the eyes, eye bulging and, in severe cases, vision loss. (Reuters)

The financing is significant because Sling is moving its lead program deeper into late-stage development at a time when several pharmaceutical companies are competing to develop alternatives to the limited number of existing TED treatments.

What Is Thyroid Eye Disease?

Thyroid eye disease is an autoimmune disorder that affects tissues around the eyes.

It is often associated with thyroid disorders, particularly Graves' disease, although it can occur in people without an active thyroid condition.

The disease can cause:

  • Eye Bulging: Inflammation can push the eyes forward, a condition known as proptosis.
  • Double Vision: Inflammation and swelling can affect the muscles controlling eye movement, leading to diplopia.
  • Eye Discomfort: Patients can experience pain, redness, swelling, dryness and sensitivity.
  • Vision Threat: In severe cases, inflammation can compress the optic nerve and potentially threaten vision.

The condition can therefore have both medical and quality-of-life consequences.

What Is Linsitinib?

Linsitinib is an oral small-molecule drug that Sling is developing specifically for TED.

The drug targets the insulin-like growth factor 1 receptor, or IGF-1R, a biological pathway involved in the autoimmune process underlying thyroid eye disease.

Blocking IGF-1R is intended to reduce the inflammatory activity that contributes to swelling and tissue expansion around the eyes.

The oral formulation is particularly important because one of the existing challenges in TED treatment is the need for therapies that are effective while also being convenient for patients.

Sling Has Already Tested the Drug in a Mid-Stage Study

Sling previously evaluated linsitinib in the Phase 2b/3 LIDS trial in patients with moderate-to-severe active TED.

The company reported positive topline results from that study in 2025, giving it a foundation for further late-stage development.

The program subsequently moved toward a larger global Phase 3 trial designed to generate the evidence needed for potential regulatory submissions.

The new financing is intended to support that next stage of development. (Investing.com South Africa)

The New Phase 3 Trial

The new capital will help fund a global Phase 3 program evaluating linsitinib in patients with thyroid eye disease.

Late-stage trials are important because they generally provide the larger and more rigorous evidence base needed for regulatory review.

For Sling, successful Phase 3 results could potentially support an application for U.S. approval.

The company will have to demonstrate that linsitinib produces meaningful improvements in TED while maintaining an acceptable safety profile.

Why an Oral Drug Could Matter

One of the major differences between linsitinib and some existing TED therapies is its oral route of administration.

Patients may prefer tablets over treatments requiring intravenous or injectable administration.

An oral medicine could potentially:

  • Simplify treatment
  • Reduce the need for infusion-center visits
  • Make treatment more convenient
  • Expand access to patients who are less comfortable with infusions

Whether those advantages translate into greater adoption will depend on clinical efficacy, safety, pricing and payer coverage.

The Existing TED Treatment Market

The TED treatment market has been developing rapidly.

One of the most important existing therapies is Horizon Therapeutics' Tepezza (teprotumumab), which was the first FDA-approved medicine specifically for thyroid eye disease.

Other companies are now developing treatments that target different parts of the disease.

That includes therapies designed to be intravenous, injectable, oral or potentially suitable for administration at home.

Sling is therefore entering a market where the differentiation between treatments may increasingly involve not just efficacy but also convenience and treatment setting.

Roche Is Also Developing a TED Treatment

Sling will face competition from Roche, which is pursuing an FDA application for Enspryng (satralizumab) in thyroid eye disease.

Roche's treatment is being studied as a subcutaneous therapy that can be administered at home.

The FDA granted the application Priority Review, with an expected decision in October 2026. (GlobeNewswire)

The development of an at-home treatment creates another possible alternative to infusion-based therapy and raises the competitive bar for convenience.

Eli Lilly Is Entering the Field Too

Eli Lilly agreed in August to acquire Merida Biosciences for up to $2.88 billion.

Merida's lead drug candidate, MER511, is being developed for Graves' disease and thyroid eye disease.

The transaction demonstrates that large pharmaceutical companies are increasingly interested in autoimmune thyroid conditions and see commercial potential in this part of the market. (Reuters)

That gives Sling another major pharmaceutical competitor to watch.

A Crowded Development Landscape

Sling is therefore competing in an emerging market that includes programs from several biotechnology and pharmaceutical companies.

Among the companies developing treatments for TED are:

  • Sling Therapeutics: Linsitinib, an oral small-molecule therapy.
  • Roche: Enspryng, a subcutaneous IL-6 inhibitor being studied in TED.
  • Eli Lilly and Merida: MER511, an investigational treatment targeting thyroid-related autoimmune disease.
  • Viridian Therapeutics: Programs designed to address both active and chronic thyroid eye disease.
  • Immunovant: Programs involving antibody-based approaches targeting the underlying autoimmune biology.

This level of competition makes differentiation particularly important.

The Market Opportunity

Thyroid eye disease affects a relatively small patient population compared with common conditions, but the disease can be highly burdensome and treatment options remain limited.

A successful therapy can therefore command significant value if it demonstrates meaningful improvements and reaches patients earlier in their disease course.

For a company such as Sling, the commercial opportunity depends on identifying patients who have active disease, securing physician adoption and obtaining payer coverage.

The Importance of Earlier Diagnosis

TED can be difficult to diagnose early because symptoms can overlap with more common eye conditions.

Patients may initially present with dry or irritated eyes, swelling, redness, changes in eye appearance and double vision.

As the disease progresses, the physical changes can become more pronounced.

That creates a potential role for better physician awareness and earlier identification of patients who could benefit from treatment.

Patient Experience Is a Major Consideration

TED can affect much more than eyesight.

Patients can experience visible changes in appearance, difficulty closing their eyes, double vision and discomfort.

These symptoms can affect work, social interactions and quality of life.

That means treatment decisions can consider both medical outcomes and functional or quality-of-life outcomes.

For oral therapies, convenience may become particularly relevant for patients who require prolonged treatment.

Why Financing Matters

The $123 million financing gives Sling the resources needed to continue a capital-intensive late-stage clinical program.

Phase 3 trials require substantial investment in:

  • Patient Recruitment: Finding and enrolling enough eligible TED patients across multiple countries and treatment centers.
  • Clinical Operations: Running sites, monitoring patients and maintaining trial infrastructure.
  • Manufacturing: Producing sufficient quantities of clinical-trial drug under appropriate manufacturing standards.
  • Regulatory Work: Preparing clinical data and documentation for eventual regulatory submissions.

The financing therefore reduces one of the immediate constraints on the company's development program.

What Investors Will Watch

The next important signals for Sling will come from the Phase 3 program.

Investors and industry participants are likely to focus on:

  • Efficacy: Whether linsitinib produces meaningful improvements in proptosis and other important TED symptoms.
  • Safety: Whether the drug remains tolerable during longer-term treatment.
  • Durability: Whether improvements persist after treatment.
  • Regulatory Progress: Whether the Phase 3 program generates enough evidence for an FDA submission.
  • Commercial Positioning: How an oral therapy would be positioned against existing and emerging injectable or infusion-based treatments.

Oral Administration Could Shape Commercial Strategy

If linsitinib reaches the market, its oral formulation could influence how physicians and patients compare therapies.

Treatment decisions could involve several factors at once: clinical efficacy, safety, convenience, dosing frequency, insurance coverage and total treatment burden.

That means Sling will eventually have to compete on the overall treatment experience, not simply the mechanism of action.

Why the Competition Is Intensifying

TED represents a relatively specialized market, but the disease is biologically well defined and has attracted several targeted therapies.

As companies generate better clinical data, the market may become increasingly segmented according to disease severity, active versus chronic disease, prior treatment, route of administration, duration of treatment and patient preference.

This could create multiple competitive niches rather than one single treatment standard.

What the Financing Says About the Market

The fact that Sling was able to raise $123 million for a late-stage TED program indicates continued investor interest in targeted autoimmune diseases.

Investors are funding the company before regulatory approval, reflecting expectations that a successful Phase 3 program could create meaningful commercial value.

However, financing alone does not establish clinical efficacy or guarantee regulatory approval.

The critical evidence will come from the company's ongoing clinical development.

Why This Matters

Sling's $123 million financing gives the company the resources to advance linsitinib into a global Phase 3 program, bringing another potential treatment closer to the U.S. market.

The program is important because linsitinib could offer an oral treatment option in a disease area where currently available therapies involve more intensive administration.

At the same time, Sling is entering a competitive field that includes Roche, Lilly and several biotechnology companies developing targeted TED therapies. (GlobeNewswire)

The eventual position of linsitinib will depend on clinical results, regulatory approval, physician adoption and how payers evaluate the treatment compared with competing options.

Looking Ahead

Sling will now focus on advancing the global Phase 3 development program for linsitinib.

The next major milestones will include trial enrollment, interim or topline clinical results and eventual regulatory interactions.

The competitive environment will also continue developing. Roche's expected FDA decision on Enspryng and Lilly's progress with MER511 could change the treatment landscape before Sling reaches commercialization. (GlobeNewswire)

For Sling, the central question is whether an oral IGF-1R-targeting treatment can demonstrate enough clinical and practical value to establish a meaningful place in TED care.

Key Takeaways

  • Sling Therapeutics raised $123 million in Series C financing to advance its thyroid eye disease program. (Reuters)
  • The funding will support a global Phase 3 clinical trial of linsitinib, Sling's experimental oral TED treatment. (Investing.com South Africa)
  • Linsitinib targets IGF-1R, a pathway involved in the biology of thyroid eye disease.
  • TED can cause eye bulging, double vision, inflammation and, in severe cases, vision loss. (Reuters)
  • Sling previously reported positive topline results from its Phase 2b/3 LIDS trial.
  • The company is entering a competitive market that includes treatments and development programs from Roche, Eli Lilly, Viridian Therapeutics and Immunovant.
  • Roche's Enspryng is being developed as a subcutaneous TED treatment and received FDA Priority Review, with a decision expected in October 2026. (GlobeNewswire)
  • Eli Lilly agreed to acquire Merida Biosciences for up to $2.88 billion, gaining access to an experimental treatment for Graves' disease and thyroid eye disease. (Reuters)
  • An oral therapy could differentiate linsitinib through convenience and reduced administration burden, although clinical efficacy, safety, pricing and payer coverage will also determine adoption.
  • The $123 million financing provides Sling with additional capital to move its lead program through the late-stage clinical development process.

What This Means for Healthcare Marketers

Sling's financing illustrates how commercial opportunity can emerge around a relatively small but highly specific patient population.

For pharmaceutical marketers, the key is understanding the complete treatment landscape rather than focusing only on the drug itself.

For TED, important signals include new drug development, clinical-trial progress, treatment routes, physician adoption, patient identification and payer coverage.

An oral treatment may create a meaningful differentiation point, but its commercial value will ultimately depend on how patients and physicians weigh convenience against efficacy, safety and access.

For healthcare intelligence teams, following competitor trials, regulatory milestones, funding events and physician activity can reveal how quickly a specialty treatment market is becoming more crowded and where new opportunities for patient engagement may emerge.